表紙
市場調查報告書

骨質疏鬆症治療藥的全球市場:各給藥途徑·各類藥物·各地區的產業分析與未來預測 (2020∼2026年)

Global Osteoporosis Drugs Market By Route of Administration By Drug Class By Region, Industry Analysis and Forecast, 2020 - 2026

出版商 KBV Research 商品編碼 941719
出版日期 內容資訊 英文 173 Pages
訂單完成後即時交付
價格
骨質疏鬆症治療藥的全球市場:各給藥途徑·各類藥物·各地區的產業分析與未來預測 (2020∼2026年) Global Osteoporosis Drugs Market By Route of Administration By Drug Class By Region, Industry Analysis and Forecast, 2020 - 2026
出版日期: 2020年05月31日內容資訊: 英文 173 Pages
簡介

全球骨質疏鬆症治療藥的市場規模今後預計將以4.4%的年複合成長率持續擴大,2025年之前達到109億美元。

本報告提供全球骨質疏鬆症治療藥的市場相關分析,提供疾病·產品概要和市場主要趨勢,市場規模趨勢預測 (今後7年份),各給藥途徑·各類藥物·及地區別詳細趨勢,主要的推動及阻礙市場要素,市場競爭環境,主要企業的簡介和策略展開情形等相關調查。

第1章 市場範圍和分析方法

第2章 市場概要

  • 簡介
  • 影響市場的主要原因

第3章 全球骨質疏鬆症治療藥市場:各給藥途徑 (RoA)

  • 口服藥
  • 注射劑
  • 其他

第4章 全球骨質疏鬆症治療藥市場:各類藥物

  • 雙膦酸鹽市場
  • 排名配體抑制劑市場
  • 副甲狀腺素療法市場
  • 抑鈣素市場
  • 雌激素抑制劑調製器 (SERM)
  • 其他

第5章 全球骨質疏鬆症治療藥市場:各地區

  • 北美市場
  • 歐洲市場
  • 亞太地區市場
  • 南美·中東·非洲 (LAMEA) 市場

第6章 企業簡介

  • Amgen, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC (GSK)
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Allergan PLC
  • Eli Lilly and Company
目錄

Title:
Global Osteoporosis Drugs Market By Route of Administration (Oral, Injectable and Other Route of Administration) By Drug Class (Bisphosphonates, Rank Ligand Inhibitors, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Other Drug Classes) By Region, Industry Analysis and Forecast, 2020 - 2026.

The Global Osteoporosis Drugs Market size is expected to reach $10.9 billion by 2026, rising at a market growth of 4.4% CAGR during the forecast period. Osteoporosis is defined as a medical condition that is characterized by low bone density and quality in humans. Bones are brittle in this medical state, which renders them more vulnerable and, in effect, more susceptible to fractures. The condition is caused by the overproduction of a hormone called parathyroid.

The condition may lead to severe fractures, which may have harmful effects on the health of the patient. Nevertheless, the condition requires treatment, including the use of osteoporosis medications. Many of the drugs on the market include selective estrogen inhibitor modulator (SERM) bisphosphonates, parathyroid hormone treatment, calcitonin, and RANK ligand inhibitors. These drugs are administered through different routes in the body, like orally or intravenously.

International Osteoporosis Foundation reports that about 200 million people worldwide suffer from osteoporosis disorder. Currently, it is believed that about 200 million people globally suffer from this illness. About 30% of the postmenopausal people have osteoporosis in the US and Europe. According to the National Institute of Health, about 53 million people in the US are either suffering from osteoporosis or at elevated risk due to low bone density. The rising consumer base for osteoporosis disorders means steady demand development over the projected period.

Bisphosphonates are a type of drug used to reduce deterioration of the bone structure and to treat osteoporosis and related diseases. These are the most widely used medications used for the treatment of osteoporosis. They are called bisphosphonates because they have two groups of PO(OH) phosphonates. They are sometimes called diphosphonates (bis-or di-+phosphonates). Data shows that they reduce the likelihood of fracture in postmenopausal women with osteoporosis.

Based on Route of Administration, the market is segmented into Oral, Injectable and Other Route of Administration. Based on Drug Class, the market is segmented into Bisphosphonates, Rank Ligand Inhibitors, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Other Drug Classes. Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC (GSK), Merck & Co., Inc., Novartis AG, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., Allergan PLC, and Eli Lilly and Company.

Strategies deployed in Osteoporosis Drugs Market

2019-Apr: Amgen and UCB announced that the U.S. Food and Drug Administration (FDA) approved EVENITY (romosozumab-aqqg) for the treatment of osteoporosis in postmenopausal women at high risk for fracture. EVENITY is the first and only bone builder with a unique dual effect that both increases bone formation and to a lesser extent reduces bone resorption (or bone loss) to rapidly reduce the risk of fracture.

2018-May: Amgen got the U.S. Food and Drug Administration (FDA) approval for the use of Prolia (denosumab) for the treatment of glucocorticoid-induced osteoporosis (GIOP) in men and women at high risk of fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.

2017-Oct: Novartis signed an agreement with Daewoong Pharmaceutical. Under this agreement, the latter company has acquired marketing and commercial rights for an osteoporosis drug from Sandoz, Novartis' generic division. By acquiring these rights, Daewoong strengthened its product lineup and secure a steady cash-flow.

2016-Sep: Amgen extended its collaboration with Dr. Reddy's Laboratories Ltd. Following the expansion, Dr. Reddy was aimed to market and distribute three of Amgen's medicines in India in the therapy areas of oncology and osteoporosis.

2016-Jun: Amgen came into partnership with Zuellig Pharma following which the latter company helps the former company in driving growth of products and therapies in multiple markets across Asia. Zuellig was aimed to support Amgen with a range of services including Commercialization, Regulatory Services and Distribution. The partnership includes the commercialization of Amgen's oncology therapeutics Neupogen, Neulastim, Vectibix, and XGEVA, and Amgen's osteoporosis medicine Prolia, in nine Asian markets.

Scope of the Study

Market Segmentation:

By Route of Administration

  • Oral
  • Injectable and
  • Other Route of Administration

By Drug Class

  • Bisphosphonates
  • Rank Ligand Inhibitors
  • Parathyroid Hormone Therapy
  • Calcitonin
  • Selective Estrogen Inhibitors Modulator (SERM) and
  • Other Drug Classes

By Geography

  • North America

US

Canada

Mexico

Rest of North America

  • Europe

Germany

UK

France

Russia

Spain

Italy

Rest of Europe

  • Asia Pacific

China

Japan

India

South Korea

Singapore

Malaysia

Rest of Asia Pacific

  • LAMEA

Brazil

Argentina

UAE

Saudi Arabia

South Africa

Nigeria

Rest of LAMEA

Companies Profiled:

  • Amgen, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC (GSK)
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceuticals Industries Ltd.
  • Allergan PLC
  • Eli Lilly and Company

Unique Offerings from KBV Research:

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 Global Osteoporosis Drugs Market, by Route of Administration
    • 1.4.2 Global Osteoporosis Drugs Market, by Drug Class
    • 1.4.3 Global Osteoporosis Drugs Market, by Geography
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
    • 2.1.2 Market Composition and Scenario
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Global Osteoporosis Drugs Market by Route of Administration

  • 3.1 Global Oral Market by Region
  • 3.2 Global Injectable Market by Region
  • 3.3 Global Other Route of Administration Market by Region

Chapter 4. Global Osteoporosis Drugs Market by Drug Class

  • 4.1 Global Bisphosphonates Market by Region
  • 4.2 Global Rank Ligand Inhibitors Market by Region
  • 4.3 Global Parathyroid Hormone Therapy Market by Region
  • 4.4 Global Calcitonin Market by Region
  • 4.5 Global Selective Estrogen Inhibitors Modulator (SERM) Market by Region
  • 4.6 Global Other Drug Class Market by Region

Chapter 5. Global Osteoporosis Drugs Market by Region

  • 5.1 North America Osteoporosis Drugs Market
    • 5.1.1 North America Osteoporosis Drugs Market by Route of Administration
      • 5.1.1.1 North America Oral Market by Country
      • 5.1.1.2 North America Injectable Market by Country
      • 5.1.1.3 North America Other Route of Administration Market by Country
    • 5.1.2 North America Osteoporosis Drugs Market by Drug Class
      • 5.1.2.1 North America Bisphosphonates Market by Country
      • 5.1.2.2 North America Rank Ligand Inhibitors Market by Country
      • 5.1.2.3 North America Parathyroid Hormone Therapy Market by Country
      • 5.1.2.4 North America Calcitonin Market by Country
      • 5.1.2.5 North America Other Drug Class Market by Country
    • 5.1.3 North America Osteoporosis Drugs Market by Country
      • 5.1.3.1 US Osteoporosis Drugs Market
        • 5.1.3.1.1 US Osteoporosis Drugs Market by Route of Administration
        • 5.1.3.1.2 US Osteoporosis Drugs Market by Drug Class
      • 5.1.3.2 Canada Osteoporosis Drugs Market
        • 5.1.3.2.1 Canada Osteoporosis Drugs Market by Route of Administration
        • 5.1.3.2.2 Canada Osteoporosis Drugs Market by Drug Class
      • 5.1.3.3 Mexico Osteoporosis Drugs Market
        • 5.1.3.3.1 Mexico Osteoporosis Drugs Market by Route of Administration
        • 5.1.3.3.2 Mexico Osteoporosis Drugs Market by Drug Class
      • 5.1.3.4 Rest of North America Osteoporosis Drugs Market
        • 5.1.3.4.1 Rest of North America Osteoporosis Drugs Market by Route of Administration
        • 5.1.3.4.2 Rest of North America Osteoporosis Drugs Market by Drug Class
  • 5.2 Europe Osteoporosis Drugs Market
    • 5.2.1 Europe Osteoporosis Drugs Market by Route of Administration
      • 5.2.1.1 Europe Oral Market by Country
      • 5.2.1.2 Europe Injectable Market by Country
      • 5.2.1.3 Europe Other Route of Administration Market by Country
    • 5.2.2 Europe Osteoporosis Drugs Market by Drug Class
      • 5.2.2.1 Europe Bisphosphonates Market by Country
      • 5.2.2.2 Europe Rank Ligand Inhibitors Market by Country
      • 5.2.2.3 Europe Parathyroid Hormone Therapy Market by Country
      • 5.2.2.4 Europe Calcitonin Market by Country
      • 5.2.2.5 Europe Other Drug Class Market by Country
    • 5.2.3 Europe Osteoporosis Drugs Market by Country
      • 5.2.3.1 Germany Osteoporosis Drugs Market
        • 5.2.3.1.1 Germany Osteoporosis Drugs Market by Route of Administration
        • 5.2.3.1.2 Germany Osteoporosis Drugs Market by Drug Class
      • 5.2.3.2 UK Osteoporosis Drugs Market
        • 5.2.3.2.1 UK Osteoporosis Drugs Market by Route of Administration
        • 5.2.3.2.2 UK Osteoporosis Drugs Market by Drug Class
      • 5.2.3.3 France Osteoporosis Drugs Market
        • 5.2.3.3.1 France Osteoporosis Drugs Market by Route of Administration
        • 5.2.3.3.2 France Osteoporosis Drugs Market by Drug Class
      • 5.2.3.4 Russia Osteoporosis Drugs Market
        • 5.2.3.4.1 Russia Osteoporosis Drugs Market by Route of Administration
        • 5.2.3.4.2 Russia Osteoporosis Drugs Market by Drug Class
      • 5.2.3.5 Spain Osteoporosis Drugs Market
        • 5.2.3.5.1 Spain Osteoporosis Drugs Market by Route of Administration
        • 5.2.3.5.2 Spain Osteoporosis Drugs Market by Drug Class
      • 5.2.3.6 Italy Osteoporosis Drugs Market
        • 5.2.3.6.1 Italy Osteoporosis Drugs Market by Route of Administration
        • 5.2.3.6.2 Italy Osteoporosis Drugs Market by Drug Class
      • 5.2.3.7 Rest of Europe Osteoporosis Drugs Market
        • 5.2.3.7.1 Rest of Europe Osteoporosis Drugs Market by Route of Administration
        • 5.2.3.7.2 Rest of Europe Osteoporosis Drugs Market by Drug Class
  • 5.3 Asia Pacific Osteoporosis Drugs Market
    • 5.3.1 Asia Pacific Osteoporosis Drugs Market by Route of Administration
      • 5.3.1.1 Asia Pacific Oral Market by Country
      • 5.3.1.2 Asia Pacific Injectable Market by Country
      • 5.3.1.3 Asia Pacific Other Route of Administration Market by Country
    • 5.3.2 Asia Pacific Osteoporosis Drugs Market by Drug Class
      • 5.3.2.1 Asia Pacific Bisphosphonates Market by Country
      • 5.3.2.2 Asia Pacific Rank Ligand Inhibitors Market by Country
      • 5.3.2.3 Asia Pacific Parathyroid Hormone Therapy Market by Country
      • 5.3.2.4 Asia Pacific Calcitonin Market by Country
      • 5.3.2.5 Asia Pacific Other Drug Class Market by Country
    • 5.3.3 Asia Pacific Osteoporosis Drugs Market by Country
      • 5.3.3.1 China Osteoporosis Drugs Market
        • 5.3.3.1.1 China Osteoporosis Drugs Market by Route of Administration
        • 5.3.3.1.2 China Osteoporosis Drugs Market by Drug Class
      • 5.3.3.2 India Osteoporosis Drugs Market
        • 5.3.3.2.1 India Osteoporosis Drugs Market by Route of Administration
        • 5.3.3.2.2 India Osteoporosis Drugs Market by Drug Class
      • 5.3.3.3 Japan Osteoporosis Drugs Market
        • 5.3.3.3.1 Japan Osteoporosis Drugs Market by Route of Administration
        • 5.3.3.3.2 Japan Osteoporosis Drugs Market by Drug Class
      • 5.3.3.4 South Korea Osteoporosis Drugs Market
        • 5.3.3.4.1 South Korea Osteoporosis Drugs Market by Route of Administration
        • 5.3.3.4.2 South Korea Osteoporosis Drugs Market by Drug Class
      • 5.3.3.5 Singapore Osteoporosis Drugs Market
        • 5.3.3.5.1 Singapore Osteoporosis Drugs Market by Route of Administration
        • 5.3.3.5.2 Singapore Osteoporosis Drugs Market by Drug Class
      • 5.3.3.6 Malaysia Osteoporosis Drugs Market
        • 5.3.3.6.1 Malaysia Osteoporosis Drugs Market by Route of Administration
        • 5.3.3.6.2 Malaysia Osteoporosis Drugs Market by Drug Class
      • 5.3.3.7 Rest of Asia Pacific Osteoporosis Drugs Market
        • 5.3.3.7.1 Rest of Asia Pacific Osteoporosis Drugs Market by Route of Administration
        • 5.3.3.7.2 Rest of Asia Pacific Osteoporosis Drugs Market by Drug Class
  • 5.4 LAMEA Osteoporosis Drugs Market
    • 5.4.1 LAMEA Osteoporosis Drugs Market by Route of Administration
      • 5.4.1.1 LAMEA Oral Market by Country
      • 5.4.1.2 LAMEA Injectable Market by Country
      • 5.4.1.3 LAMEA Other Route of Administration Market by Country
    • 5.4.2 LAMEA Osteoporosis Drugs Market by Drug Class
      • 5.4.2.1 LAMEA Bisphosphonates Market by Country
      • 5.4.2.2 LAMEA Rank Ligand Inhibitors Market by Country
      • 5.4.2.3 LAMEA Parathyroid Hormone Therapy Market by Country
      • 5.4.2.4 LAMEA Calcitonin Market by Country
      • 5.4.2.5 LAMEA Other Drug Class Market by Country
    • 5.4.3 LAMEA Osteoporosis Drugs Market by Country
      • 5.4.3.1 Brazil Osteoporosis Drugs Market
        • 5.4.3.1.1 Brazil Osteoporosis Drugs Market by Route of Administration
        • 5.4.3.1.2 Brazil Osteoporosis Drugs Market by Drug Class
      • 5.4.3.2 Argentina Osteoporosis Drugs Market
        • 5.4.3.2.1 Argentina Osteoporosis Drugs Market by Route of Administration
        • 5.4.3.2.2 Argentina Osteoporosis Drugs Market by Drug Class
      • 5.4.3.3 UAE Osteoporosis Drugs Market
        • 5.4.3.3.1 UAE Osteoporosis Drugs Market by Route of Administration
        • 5.4.3.3.2 UAE Osteoporosis Drugs Market by Drug Class
      • 5.4.3.4 Saudi Arabia Osteoporosis Drugs Market
        • 5.4.3.4.1 Saudi Arabia Osteoporosis Drugs Market by Route of Administration
        • 5.4.3.4.2 Saudi Arabia Osteoporosis Drugs Market by Drug Class
      • 5.4.3.5 South Africa Osteoporosis Drugs Market
        • 5.4.3.5.1 South Africa Osteoporosis Drugs Market by Route of Administration
        • 5.4.3.5.2 South Africa Osteoporosis Drugs Market by Drug Class
      • 5.4.3.6 Nigeria Osteoporosis Drugs Market
        • 5.4.3.6.1 Nigeria Osteoporosis Drugs Market by Route of Administration
        • 5.4.3.6.2 Nigeria Osteoporosis Drugs Market by Drug Class
      • 5.4.3.7 Rest of LAMEA Osteoporosis Drugs Market
        • 5.4.3.7.1 Rest of LAMEA Osteoporosis Drugs Market by Route of Administration
        • 5.4.3.7.2 Rest of LAMEA Osteoporosis Drugs Market by Drug Class

Chapter 6. Company Profiles

  • 6.1 Amgen, Inc.
    • 6.1.1 Company Overview
    • 6.1.2 Financial Analysis
    • 6.1.3 Research & Development Expense
    • 6.1.4 Recent strategies and developments:
      • 6.1.4.1 Partnerships, Collaborations, and Agreements:
      • 6.1.4.2 Approvals:
  • 6.2 F. Hoffmann-La Roche Ltd.
    • 6.2.1 Company Overview
    • 6.2.2 Financial Analysis
    • 6.2.3 Segmental and Regional Analysis
    • 6.2.4 Research & Development Expense
  • 6.3 GlaxoSmithKline PLC (GSK)
    • 6.3.1 Company Overview
    • 6.3.2 Financial Analysis
    • 6.3.3 Segmental and Regional Analysis
    • 6.3.4 Research & Development Expense
  • 6.4 Merck & Co., Inc.
    • 6.4.1 Company Overview
    • 6.4.2 Financial Analysis
    • 6.4.3 Segmental and Regional Analysis
    • 6.4.4 Research & Development Expenses
  • 6.5 Novartis AG
    • 6.5.1 Company Overview
    • 6.5.2 Financial Analysis
    • 6.5.3 Segmental and Regional Analysis
    • 6.5.4 Recent strategies and developments:
      • 6.5.4.1 Partnerships, Collaborations, and Agreements:
  • 6.6 Pfizer, Inc.
    • 6.6.1 Company Overview
    • 6.6.2 Financial Analysis
    • 6.6.3 Segmental and Regional Analysis
    • 6.6.4 Research & Development Expense
  • 6.7 Sun Pharmaceutical Industries Ltd.
    • 6.7.1 Company Overview
    • 6.7.2 Financial Analysis
    • 6.7.3 Regional Analysis
    • 6.7.4 Research & Development Expense
  • 6.8 Teva Pharmaceutical Industries Ltd.
    • 6.8.1 Company Overview
    • 6.8.2 Financial Analysis
    • 6.8.3 Regional Analysis
    • 6.8.4 Research & Development Expenses
  • 6.9 Allergan PLC
    • 6.9.1 Company Overview
    • 6.9.2 Financial Analysis
    • 6.9.3 Segmental and Regional Analysis
    • 6.9.4 Research & Development Expense
  • 6.1 Eli Lilly and Company
    • 6.10.1 Company Overview
    • 6.10.2 Financial Analysis
    • 6.10.3 Regional Analysis
    • 6.10.4 Research & Development Expense

LIST OF TABLES

  • TABLE 1. GLOBAL OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
  • TABLE 2. GLOBAL OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
  • TABLE 3. GLOBAL OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
  • TABLE 4. GLOBAL OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
  • TABLE 5. GLOBAL ORAL MARKET BY REGION, 2016 - 2019, USD MILLION
  • TABLE 6. GLOBAL ORAL MARKET BY REGION, 2020 - 2026, USD MILLION
  • TABLE 7. GLOBAL INJECTABLE MARKET BY REGION, 2016 - 2019, USD MILLION
  • TABLE 8. GLOBAL INJECTABLE MARKET BY REGION, 2020 - 2026, USD MILLION
  • TABLE 9. GLOBAL OTHER ROUTE OF ADMINISTRATION MARKET BY REGION, 2016 - 2019, USD MILLION
  • TABLE 10. GLOBAL OTHER ROUTE OF ADMINISTRATION MARKET BY REGION, 2020 - 2026, USD MILLION
  • TABLE 11. GLOBAL OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
  • TABLE 12. GLOBAL OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
  • TABLE 13. GLOBAL BISPHOSPHONATES MARKET BY REGION, 2016 - 2019, USD MILLION
  • TABLE 14. GLOBAL BISPHOSPHONATES MARKET BY REGION, 2020 - 2026, USD MILLION
  • TABLE 15. GLOBAL RANK LIGAND INHIBITORS MARKET BY REGION, 2016 - 2019, USD MILLION
  • TABLE 16. GLOBAL RANK LIGAND INHIBITORS MARKET BY REGION, 2020 - 2026, USD MILLION
  • TABLE 17. GLOBAL PARATHYROID HORMONE THERAPY MARKET BY REGION, 2016 - 2019, USD MILLION
  • TABLE 18. GLOBAL PARATHYROID HORMONE THERAPY MARKET BY REGION, 2020 - 2026, USD MILLION
  • TABLE 19. GLOBAL CALCITONIN MARKET BY REGION, 2016 - 2019, USD MILLION
  • TABLE 20. GLOBAL CALCITONIN MARKET BY REGION, 2020 - 2026, USD MILLION
  • TABLE 21. GLOBAL SELECTIVE ESTROGEN INHIBITORS MODULATOR (SERM) MARKET BY REGION, 2016 - 2019, USD MILLION
  • TABLE 22. GLOBAL SELECTIVE ESTROGEN INHIBITORS MODULATOR (SERM) MARKET BY REGION, 2020 - 2026, USD MILLION
  • TABLE 23. GLOBAL OTHER DRUG CLASS MARKET BY REGION, 2016 - 2019, USD MILLION
  • TABLE 24. GLOBAL OTHER DRUG CLASS MARKET BY REGION, 2020 - 2026, USD MILLION
  • TABLE 25. GLOBAL OSTEOPOROSIS DRUGS MARKET BY REGION, 2016 - 2019, USD MILLION
  • TABLE 26. GLOBAL OSTEOPOROSIS DRUGS MARKET BY REGION, 2020 - 2026, USD MILLION
  • TABLE 27. NORTH AMERICA OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
  • TABLE 28. NORTH AMERICA OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
  • TABLE 29. NORTH AMERICA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
  • TABLE 30. NORTH AMERICA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
  • TABLE 31. NORTH AMERICA ORAL MARKET BY COUNTRY, 2016 - 2019, USD MILLION
  • TABLE 32. NORTH AMERICA ORAL MARKET BY COUNTRY, 2020 - 2026, USD MILLION
  • TABLE 33. NORTH AMERICA INJECTABLE MARKET BY COUNTRY, 2016 - 2019, USD MILLION
  • TABLE 34. NORTH AMERICA INJECTABLE MARKET BY COUNTRY, 2020 - 2026, USD MILLION
  • TABLE 35. NORTH AMERICA OTHER ROUTE OF ADMINISTRATION MARKET BY COUNTRY, 2016 - 2019, USD MILLION
  • TABLE 36. NORTH AMERICA OTHER ROUTE OF ADMINISTRATION MARKET BY COUNTRY, 2020 - 2026, USD MILLION
  • TABLE 37. NORTH AMERICA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
  • TABLE 38. NORTH AMERICA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
  • TABLE 39. NORTH AMERICA BISPHOSPHONATES MARKET BY COUNTRY, 2016 - 2019, USD MILLION
  • TABLE 40. NORTH AMERICA BISPHOSPHONATES MARKET BY COUNTRY, 2020 - 2026, USD MILLION
  • TABLE 41. NORTH AMERICA RANK LIGAND INHIBITORS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
  • TABLE 42. NORTH AMERICA RANK LIGAND INHIBITORS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
  • TABLE 43. NORTH AMERICA PARATHYROID HORMONE THERAPY MARKET BY COUNTRY, 2016 - 2019, USD MILLION
  • TABLE 44. NORTH AMERICA PARATHYROID HORMONE THERAPY MARKET BY COUNTRY, 2020 - 2026, USD MILLION
  • TABLE 45. NORTH AMERICA CALCITONIN MARKET BY COUNTRY, 2016 - 2019, USD MILLION
  • TABLE 46. NORTH AMERICA CALCITONIN MARKET BY COUNTRY, 2020 - 2026, USD MILLION
  • TABLE 47. NORTH AMERICA OTHER DRUG CLASS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
  • TABLE 48. NORTH AMERICA OTHER DRUG CLASS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
  • TABLE 49. NORTH AMERICA OSTEOPOROSIS DRUGS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
  • TABLE 50. NORTH AMERICA OSTEOPOROSIS DRUGS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
  • TABLE 51. US OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
  • TABLE 52. US OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
  • TABLE 53. US OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
  • TABLE 54. US OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
  • TABLE 55. US OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
  • TABLE 56. US OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
  • TABLE 57. CANADA OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
  • TABLE 58. CANADA OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
  • TABLE 59. CANADA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
  • TABLE 60. CANADA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
  • TABLE 61. CANADA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
  • TABLE 62. CANADA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
  • TABLE 63. MEXICO OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
  • TABLE 64. MEXICO OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
  • TABLE 65. MEXICO OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
  • TABLE 66. MEXICO OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
  • TABLE 67. MEXICO OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
  • TABLE 68. REST OF NORTH AMERICA OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
  • TABLE 69. REST OF NORTH AMERICA OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
  • TABLE 70. REST OF NORTH AMERICA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
  • TABLE 71. REST OF NORTH AMERICA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
  • TABLE 72. REST OF NORTH AMERICA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
  • TABLE 73. REST OF NORTH AMERICA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
  • TABLE 74. EUROPE OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
  • TABLE 75. EUROPE OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
  • TABLE 76. EUROPE OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
  • TABLE 77. EUROPE OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
  • TABLE 78. EUROPE ORAL MARKET BY COUNTRY, 2016 - 2019, USD MILLION
  • TABLE 79. EUROPE ORAL MARKET BY COUNTRY, 2020 - 2026, USD MILLION
  • TABLE 80. EUROPE INJECTABLE MARKET BY COUNTRY, 2016 - 2019, USD MILLION
  • TABLE 81. EUROPE INJECTABLE MARKET BY COUNTRY, 2020 - 2026, USD MILLION
  • TABLE 82. EUROPE OTHER ROUTE OF ADMINISTRATION MARKET BY COUNTRY, 2016 - 2019, USD MILLION
  • TABLE 83. EUROPE OTHER ROUTE OF ADMINISTRATION MARKET BY COUNTRY, 2020 - 2026, USD MILLION
  • TABLE 84. EUROPE OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
  • TABLE 85. EUROPE OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
  • TABLE 86. EUROPE BISPHOSPHONATES MARKET BY COUNTRY, 2016 - 2019, USD MILLION
  • TABLE 87. EUROPE BISPHOSPHONATES MARKET BY COUNTRY, 2020 - 2026, USD MILLION
  • TABLE 88. EUROPE RANK LIGAND INHIBITORS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
  • TABLE 89. EUROPE RANK LIGAND INHIBITORS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
  • TABLE 90. EUROPE PARATHYROID HORMONE THERAPY MARKET BY COUNTRY, 2016 - 2019, USD MILLION
  • TABLE 91. EUROPE PARATHYROID HORMONE THERAPY MARKET BY COUNTRY, 2020 - 2026, USD MILLION
  • TABLE 92. EUROPE CALCITONIN MARKET BY COUNTRY, 2016 - 2019, USD MILLION
  • TABLE 93. EUROPE CALCITONIN MARKET BY COUNTRY, 2020 - 2026, USD MILLION
  • TABLE 94. EUROPE OTHER DRUG CLASS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
  • TABLE 95. EUROPE OTHER DRUG CLASS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
  • TABLE 96. EUROPE OSTEOPOROSIS DRUGS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
  • TABLE 97. EUROPE OSTEOPOROSIS DRUGS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
  • TABLE 98. GERMANY OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
  • TABLE 99. GERMANY OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
  • TABLE 100. GERMANY OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
  • TABLE 101. GERMANY OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
  • TABLE 102. GERMANY OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
  • TABLE 103. GERMANY OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
  • TABLE 104. UK OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
  • TABLE 105. UK OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
  • TABLE 106. UK OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
  • TABLE 107. UK OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
  • TABLE 108. UK OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
  • TABLE 109. UK OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
  • TABLE 110. FRANCE OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
  • TABLE 111. FRANCE OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
  • TABLE 112. FRANCE OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
  • TABLE 113. FRANCE OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
  • TABLE 114. FRANCE OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
  • TABLE 115. FRANCE OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
  • TABLE 116. RUSSIA OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
  • TABLE 117. RUSSIA OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
  • TABLE 118. RUSSIA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
  • TABLE 119. RUSSIA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
  • TABLE 120. RUSSIA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
  • TABLE 121. RUSSIA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
  • TABLE 122. SPAIN OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
  • TABLE 123. SPAIN OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
  • TABLE 124. SPAIN OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
  • TABLE 125. SPAIN OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
  • TABLE 126. SPAIN OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
  • TABLE 127. SPAIN OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
  • TABLE 128. ITALY OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
  • TABLE 129. ITALY OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
  • TABLE 130. ITALY OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
  • TABLE 131. ITALY OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
  • TABLE 132. ITALY OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
  • TABLE 133. ITALY OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
  • TABLE 134. REST OF EUROPE OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
  • TABLE 135. REST OF EUROPE OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
  • TABLE 136. REST OF EUROPE OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
  • TABLE 137. REST OF EUROPE OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
  • TABLE 138. REST OF EUROPE OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
  • TABLE 139. REST OF EUROPE OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
  • TABLE 140. ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
  • TABLE 141. ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
  • TABLE 142. ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
  • TABLE 143. ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
  • TABLE 144. ASIA PACIFIC ORAL MARKET BY COUNTRY, 2016 - 2019, USD MILLION
  • TABLE 145. ASIA PACIFIC ORAL MARKET BY COUNTRY, 2020 - 2026, USD MILLION
  • TABLE 146. ASIA PACIFIC INJECTABLE MARKET BY COUNTRY, 2016 - 2019, USD MILLION
  • TABLE 147. ASIA PACIFIC INJECTABLE MARKET BY COUNTRY, 2020 - 2026, USD MILLION
  • TABLE 148. ASIA PACIFIC OTHER ROUTE OF ADMINISTRATION MARKET BY COUNTRY, 2016 - 2019, USD MILLION
  • TABLE 149. ASIA PACIFIC OTHER ROUTE OF ADMINISTRATION MARKET BY COUNTRY, 2020 - 2026, USD MILLION
  • TABLE 150. ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
  • TABLE 151. ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
  • TABLE 152. ASIA PACIFIC BISPHOSPHONATES MARKET BY COUNTRY, 2016 - 2019, USD MILLION
  • TABLE 153. ASIA PACIFIC BISPHOSPHONATES MARKET BY COUNTRY, 2020 - 2026, USD MILLION
  • TABLE 154. ASIA PACIFIC RANK LIGAND INHIBITORS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
  • TABLE 155. ASIA PACIFIC RANK LIGAND INHIBITORS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
  • TABLE 156. ASIA PACIFIC PARATHYROID HORMONE THERAPY MARKET BY COUNTRY, 2016 - 2019, USD MILLION
  • TABLE 157. ASIA PACIFIC PARATHYROID HORMONE THERAPY MARKET BY COUNTRY, 2020 - 2026, USD MILLION
  • TABLE 158. ASIA PACIFIC CALCITONIN MARKET BY COUNTRY, 2016 - 2019, USD MILLION
  • TABLE 159. ASIA PACIFIC CALCITONIN MARKET BY COUNTRY, 2020 - 2026, USD MILLION
  • TABLE 160. ASIA PACIFIC OTHER DRUG CLASS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
  • TABLE 161. ASIA PACIFIC OTHER DRUG CLASS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
  • TABLE 162. ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
  • TABLE 163. ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
  • TABLE 164. CHINA OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
  • TABLE 165. CHINA OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
  • TABLE 166. CHINA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
  • TABLE 167. CHINA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
  • TABLE 168. CHINA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
  • TABLE 169. CHINA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
  • TABLE 170. INDIA OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
  • TABLE 171. INDIA OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
  • TABLE 172. INDIA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
  • TABLE 173. INDIA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
  • TABLE 174. INDIA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
  • TABLE 175. INDIA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
  • TABLE 176. JAPAN OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
  • TABLE 177. JAPAN OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
  • TABLE 178. JAPAN OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
  • TABLE 179. JAPAN OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
  • TABLE 180. JAPAN OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
  • TABLE 181. JAPAN OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
  • TABLE 182. SOUTH KOREA OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
  • TABLE 183. SOUTH KOREA OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
  • TABLE 184. SOUTH KOREA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
  • TABLE 185. SOUTH KOREA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
  • TABLE 186. SOUTH KOREA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
  • TABLE 187. SOUTH KOREA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
  • TABLE 188. SINGAPORE OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
  • TABLE 189. SINGAPORE OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
  • TABLE 190. SINGAPORE OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
  • TABLE 191. SINGAPORE OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
  • TABLE 192. SINGAPORE OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
  • TABLE 193. SINGAPORE OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
  • TABLE 194. MALAYSIA OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
  • TABLE 195. MALAYSIA OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
  • TABLE 196. MALAYSIA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
  • TABLE 197. MALAYSIA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
  • TABLE 198. MALAYSIA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
  • TABLE 199. MALAYSIA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
  • TABLE 200. REST OF ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
  • TABLE 201. REST OF ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
  • TABLE 202. REST OF ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
  • TABLE 203. REST OF ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
  • TABLE 204. REST OF ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
  • TABLE 205. REST OF ASIA PACIFIC OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
  • TABLE 206. LAMEA OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
  • TABLE 207. LAMEA OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
  • TABLE 208. LAMEA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
  • TABLE 209. LAMEA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
  • TABLE 210. LAMEA ORAL MARKET BY COUNTRY, 2016 - 2019, USD MILLION
  • TABLE 211. LAMEA ORAL MARKET BY COUNTRY, 2020 - 2026, USD MILLION
  • TABLE 212. LAMEA INJECTABLE MARKET BY COUNTRY, 2016 - 2019, USD MILLION
  • TABLE 213. LAMEA INJECTABLE MARKET BY COUNTRY, 2020 - 2026, USD MILLION
  • TABLE 214. LAMEA OTHER ROUTE OF ADMINISTRATION MARKET BY COUNTRY, 2016 - 2019, USD MILLION
  • TABLE 215. LAMEA OTHER ROUTE OF ADMINISTRATION MARKET BY COUNTRY, 2020 - 2026, USD MILLION
  • TABLE 216. LAMEA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
  • TABLE 217. LAMEA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
  • TABLE 218. LAMEA BISPHOSPHONATES MARKET BY COUNTRY, 2016 - 2019, USD MILLION
  • TABLE 219. LAMEA BISPHOSPHONATES MARKET BY COUNTRY, 2020 - 2026, USD MILLION
  • TABLE 220. LAMEA RANK LIGAND INHIBITORS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
  • TABLE 221. LAMEA RANK LIGAND INHIBITORS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
  • TABLE 222. LAMEA PARATHYROID HORMONE THERAPY MARKET BY COUNTRY, 2016 - 2019, USD MILLION
  • TABLE 223. LAMEA PARATHYROID HORMONE THERAPY MARKET BY COUNTRY, 2020 - 2026, USD MILLION
  • TABLE 224. LAMEA CALCITONIN MARKET BY COUNTRY, 2016 - 2019, USD MILLION
  • TABLE 225. LAMEA CALCITONIN MARKET BY COUNTRY, 2020 - 2026, USD MILLION
  • TABLE 226. LAMEA OTHER DRUG CLASS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
  • TABLE 227. LAMEA OTHER DRUG CLASS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
  • TABLE 228. LAMEA OSTEOPOROSIS DRUGS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
  • TABLE 229. LAMEA OSTEOPOROSIS DRUGS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
  • TABLE 230. BRAZIL OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
  • TABLE 231. BRAZIL OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
  • TABLE 232. BRAZIL OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
  • TABLE 233. BRAZIL OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
  • TABLE 234. BRAZIL OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
  • TABLE 235. BRAZIL OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
  • TABLE 236. ARGENTINA OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
  • TABLE 237. ARGENTINA OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
  • TABLE 238. ARGENTINA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
  • TABLE 239. ARGENTINA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
  • TABLE 240. ARGENTINA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
  • TABLE 241. ARGENTINA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
  • TABLE 242. UAE OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
  • TABLE 243. UAE OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
  • TABLE 244. UAE OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
  • TABLE 245. UAE OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
  • TABLE 246. UAE OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
  • TABLE 247. UAE OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
  • TABLE 248. SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
  • TABLE 249. SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
  • TABLE 250. SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
  • TABLE 251. SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
  • TABLE 252. SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
  • TABLE 253. SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
  • TABLE 254. SOUTH AFRICA OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
  • TABLE 255. SOUTH AFRICA OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
  • TABLE 256. SOUTH AFRICA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
  • TABLE 257. SOUTH AFRICA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
  • TABLE 258. SOUTH AFRICA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
  • TABLE 259. SOUTH AFRICA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
  • TABLE 260. NIGERIA OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
  • TABLE 261. NIGERIA OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
  • TABLE 262. NIGERIA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
  • TABLE 263. NIGERIA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
  • TABLE 264. NIGERIA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
  • TABLE 265. NIGERIA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
  • TABLE 266. REST OF LAMEA OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
  • TABLE 267. REST OF LAMEA OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
  • TABLE 268. REST OF LAMEA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
  • TABLE 269. REST OF LAMEA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
  • TABLE 270. REST OF LAMEA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
  • TABLE 271. REST OF LAMEA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
  • TABLE 272. KEY INFORMATION - AMGEN, INC.
  • TABLE 273. KEY INFORMATION - F. HOFFMANN-LA ROCHE LTD.
  • TABLE 274. KEY INFORMATION - GLAXOSMITHKLINE PLC (GSK)
  • TABLE 275. KEY INFORMATION - MERCK & CO., INC.
  • TABLE 276. KEY INFORMATION - NOVARTIS AG
  • TABLE 277. KEY INFORMATION - PFIZER, INC.
  • TABLE 278. KEY INFORMATION - SUN PHARMACEUTICAL INDUSTRIES LTD.
  • TABLE 279. KEY INFORMATION - TEVA PHARMACEUTICALS INDUSTRIES LTD.
  • TABLE 280. KEY INFORMATION - ALLERGAN PLC
  • TABLE 281. KEY INFORMATION - ELI LILLY AND COMPANY

LIST OF FIGURES

  • FIG 1. METHODOLOGY FOR THE RESEARCH